C-Ray Therapeutics, a Chengdu-based radiopharmaceuticals specialist, announced a master radioisotope supply agreement with SHINE Technologies, LLC, a U.S. nuclear technology company. SHINE will supply carrier-free Lu-177 meeting GMP standards and China/U.S. regulatory requirements on a long-term basis, with C-Ray serving as SHINE’s exclusive distribution partner in mainland China for this critical therapeutic medical isotope used in targeted radionuclide therapy for prostate cancer and neuroendocrine tumors (NETs).
GMP-compliant; meets China NMPA and U.S. FDA requirements
Distribution Rights
C-Ray: Exclusive mainland China distributor for SHINE Lu-177
Target Customers
Chinese radiopharmaceutical companies, biotech firms, medical institutions
Lu-177: Therapeutic Medical Isotope Profile
Attribute
Lu-177 Specification
Clinical Application
Physical Half-Life
6.7 days – optimal for therapy logistics and patient dosing
Allows centralized production and regional distribution
Beta-Ray Energy
Medium-energy beta emissions (0.497 MeV max)
Effective tumor cell killing with limited tissue penetration (tumor-specific cytotoxicity)
Imaging Capability
Gamma emissions (208 keV) enable SPECT imaging
Theranostic approach – simultaneous therapy and treatment monitoring
Primary Indications
Prostate cancer (PSMA-targeting), neuroendocrine tumors (NETs)
Lutathera (Novartis) established market; Pluvicto (Novartis) driving prostate cancer adoption
Global Utilization
Most widely used therapeutic medical nuclide in targeted radionuclide therapy
$2+ billion annual market growing at 20%+ CAGR
Strategic Context & Market Impact
Factor
Implication
China Radiopharmaceutical Gap
Domestic Lu-177 production limited – reliance on imports from Russia, South Africa, Australia; supply security risk for growing theranostics market
SHINE Technology Advantage
U.S.-based accelerator production – carrier-free Lu-177 (higher specific activity vs. reactor-produced); GMP quality supports regulatory filings
C-Ray Distribution Network
Exclusive China rights – positions as critical infrastructure provider for 50+ radiopharmaceutical developers and 300+ nuclear medicine centers
Theranostics Market Growth
China PSMA-targeting and NET therapies expanding rapidly; Lu-177 demand projected 3x increase 2025–2028
Geopolitical Consideration
U.S.-China nuclear materials trade requires strict export controls; agreement demonstrates compliance pathway for medical isotope commerce
Supply Timeline:Q2 2026 initial shipments; full-scale distribution 2027 following NMPA import license finalization
Revenue Potential: C-Ray RMB 200–400 million annual distribution revenue by 2028; SHINE $50+ million China export value
Forward‑Looking Statements This brief contains forward‑looking statements regarding supply chain establishment, regulatory approval timelines, and market penetration for Lu-177 in China. Actual results may differ due to nuclear materials export licensing complexity, competitive dynamics with domestic Lu-177 production (CNNC), and radiopharmaceutical therapy adoption rates in Chinese oncology practice.-Fineline Info & Tech
